Altimmune Valuation Multiples

Altimmune Overview

About Altimmune

Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.

Founded

2005

HQ

Employees

59

Website

altimmune.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $31K

EBITDA: ($105M)

EV

$202M

Valuation Multiples

Multiples.vc

Start free trial

Altimmune Financials

Altimmune reported last 12-month revenue of $31K and negative EBITDA of ($105M).

In the same LTM period, Altimmune generated $31K in gross profit, ($105M) in EBITDA losses, and had net loss of ($99M).

Altimmune P&L

In the most recent fiscal year, Altimmune reported revenue of $41K and EBITDA of ($87M).

Altimmune expects next 12-month revenue of XXX and NTM EBITDA of XXX

Altimmune Stock Performance

Altimmune has current market cap of $440M, and enterprise value of $202M.

Altimmune's stock price is $3.38.

Altimmune Valuation Multiples

Altimmune trades at 6418.0x EV/Revenue multiple, and (1.9x) EV/EBITDA.

Altimmune Financial Valuation Multiples

As of April 10, 2026, Altimmune has market cap of $440M and EV of $202M.

Equity research analysts estimate Altimmune's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Altimmune has a P/E ratio of (4.4x).

Altimmune Margins & Growth Rates

Altimmune's revenue in the last 12 month declined by (86%).

Altimmune's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.6M for the same period.

Altimmune's rule of 40 is (2132169%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Altimmune's rule of X is (2132296%) (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Altimmune Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Altimmune M&A Activity

Altimmune acquired XXX companies to date.

Last acquisition by Altimmune was on XXXXXXXX, XXXXX. Altimmune acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Altimmune Investment Activity

Altimmune invested in XXX companies to date.

Altimmune made its latest investment on XXXXXXXX, XXXXX. Altimmune invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).